The study’s aim was to explore
the effect of venlafaxine,
valsartan, and pramipexole on spermatogenesis. It was hypothesized
that these drugs may affect the male fertility because of their long-term
use in treatment of depression, hypertension, and Parkinson’s
diseases. Male rats were given venlafaxine, valsartan, and pramipexole
at low- and high-dose levels orally once daily for 10 weeks. Testosterone
(25 mg/kg) was given as a standard via an intramuscular route once
weekly. Rats were sacrificed after blood collection by cardiac puncture,
and testes were removed. Sperm parameters were examined from spermatozoa
of the cauda epididymis, and testes were treated for histopathological
analysis. Results showed nonsignificant effect of venlafaxine on the
sperm count, whereas a decreased sperm count was noted in all the
treatment groups as compared to that of the control except valsartan
at a low dose, which significantly (
p
< 0.001)
raised the sperm count (96.26 ± 2.4) in reference with the control
value (49.13 ± 2.3). Treatments had variable effects on total
sperm motility and morphological parameters, but valsartan at a low
dose showed maximum sperm motility (71.55 ± 0.7) among all. DNA
integrity of spermatozoa remained intact in all groups. Luteinizing
hormone and follicle-stimulating hormone levels decreased, and testosterone
levels increased in all treatment groups as compared to control values,
which indicate fertility. Histopathology revealed normal texture of
testes with venlafaxine and valsartan, but testicular damage occurred
with high-dose pramipexole. It is concluded that the use of venlafaxine,
valsartan, and pramipexole at a low dose is devoid of any harmful
effect on spermatogenesis, whereas pramipexole at a high dose adversely
affect it.